Profil
Paolo Tombesi formerly worked at Novartis Holding Japan KK, as Chief Financial Officer & Managing Director, Insmed, Inc., as Chief Financial Officer from 2017 to 2019, Turning Point Therapeutics, Inc., as Executive VP, Chief Financial & Accounting Officer from 2021 to 2022, Novartis Pharmaceuticals Corp., as VP, Chief Financial & Administrative Officer from 2017 to 2019, Novartis Vaccines & Diagnostics, Inc., as President, and Epizyme, Inc., as Chief Financial Officer from 2019 to 2021.
Mr. Tombesi received his undergraduate degree from Sapienza University of Rome.
Anciens postes connus de Paolo Tombesi
| Sociétés | Poste | Fin |
|---|---|---|
| TURG POIN | Director of Finance/CFO | 01/09/2022 |
| EPIZYME, INC. | Director of Finance/CFO | 16/07/2021 |
| INSMED INCORPORATED | Director of Finance/CFO | 02/06/2019 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Director of Finance/CFO | 01/06/2019 |
| Novartis Holding Japan KK | Director of Finance/CFO | - |
Formation de Paolo Tombesi
| Sapienza University of Rome | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INSMED INCORPORATED | Health Technology |
| Entreprise privées | 5 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
| Novartis Holding Japan KK |
